These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31718825)

  • 1. Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials.
    Hideo-Kajita A; Garcia-Garcia HM; Kolm P; Azizi V; Ozaki Y; Dan K; Ince H; Kische S; Abizaid A; Töelg R; Lemos PA; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Wijns W; Lefèvre T; Windecker S; Waksman R; Haude M;
    Int J Cardiol; 2020 Feb; 300():60-65. PubMed ID: 31718825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.
    Garcia-Garcia HM; Haude M; Kuku K; Hideo-Kajita A; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
    Int J Cardiol; 2018 Mar; 255():22-28. PubMed ID: 29292064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
    Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.
    Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R
    Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIOFLOW-III satellite-One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance.
    Kornowski R; Roguin A; Danenberg H; Assa HV; Abergel E; Rozenbaum E; Guetta V; Landes U; Jabara R; Merdler A; Segev A; Mosseri M; Assali A
    Cardiovasc Revasc Med; 2017; 18(5):338-343. PubMed ID: 28302466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BIOFLOW-III Italian Satellite Registry: 18-month results of the Orsiro stent in an all-comer high-risk population.
    Bartorelli AL; Versaci F; Briguori C; Tomai F; Aprigliano G; Poli A; Vigna C; Marinucci L; My L; Masi F; Turturo M
    J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):464-470. PubMed ID: 30994511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial.
    Lefèvre T; Haude M; Neumann FJ; Stangl K; Skurk C; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Macia JC; Windecker S
    JACC Cardiovasc Interv; 2018 May; 11(10):995-1002. PubMed ID: 29798778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent.
    Waltenberger J; Brachmann J; van der Heyden J; Richardt G; Fröbert O; Seige M; Friedrich G; Erglis A; Winkens M; Hegeler-Molkewehrum C; Neef M; Hoffmann S;
    Cardiovasc Revasc Med; 2020 Jan; 21(1):63-69. PubMed ID: 30922870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
    von Birgelen C; Zocca P; Buiten RA; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Anthonio RL; Stoel MG; Somi S; Hartmann M; Linssen GCM; Doggen CJM; Kok MM
    Lancet; 2018 Oct; 392(10154):1235-1245. PubMed ID: 30253879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months.
    Saito S; Toelg R; Witzenbichler B; Haude M; Masotti M; Salmeron R; Witkowski A; Uematsu M; Takahashi A; Waksman R; Slagboom T
    EuroIntervention; 2019 Dec; 15(11):e1006-e1013. PubMed ID: 31235458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials.
    Lipinski MJ; Forrestal BJ; Iantorno M; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2018 Jan; 19(1 Pt A):5-11. PubMed ID: 29221958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Doros G; Massaro JM; Kandzari DE; Waksman R; Koolen JJ; Cutlip DE; Mauri L
    Am Heart J; 2017 Nov; 193():35-45. PubMed ID: 29129253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
    Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Hansen HS; Jensen SE; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Am Heart J; 2015 Aug; 170(2):210-5. PubMed ID: 26299216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.
    Verheye S; Wlodarczak A; Montorsi P; Torzewski J; Bennett J; Haude M; Starmer G; Buck T; Wiemer M; Nuruddin AAB; Yan BP; Lee MK
    Catheter Cardiovasc Interv; 2021 Jul; 98(1):E1-E8. PubMed ID: 32881396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.
    Haude M; Ince H; Kische S; Abizaid A; Tölg R; Alves Lemos P; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Wijns W; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2017 Jul; 13(4):432-439. PubMed ID: 28504239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
    Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial.
    Jakobsen L; Christiansen EH; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Madsen M; Raungaard B; Jensen SE; Christensen MK; Hansen HS; Jensen LO
    Am Heart J; 2018 Aug; 202():49-53. PubMed ID: 29807307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.